Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Ribo Life Science CoHKSE:06938 -4.07%9 PS Ratio is 16.94 as of Sep. 12, 2026, which is 71% below its 10-year median of 58.35. GuruFocus rates HKSE:06938 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 936 Biotechnology companies, Suzhou Ribo Life Science Co ranks worse than 63.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Suzhou Ribo Life Science Co's share price is HK$54.15.
Suzhou Ribo Life Science Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$3.20. Hence, Suzhou Ribo Life Science Co's PS Ratio for today is 16.94.
The historical rank and industry rank for Suzhou Ribo Life Science Co's PS Ratio or its related term are showing as below:
HKSE:06938'
s PS Ratio Range Over the Past 10 Years
Min: 16.94 Med: 58.35 Max: 80.89
Current: 16.94
During the past 3 years, Suzhou Ribo Life Science Co's highest PS Ratio was 80.89. The lowest was 16.94. And the median was 58.35.
HKSE:06938's PS Ratio is ranked worse than 63.78% of 936
companies
in the Biotechnology industry
Industry Median: 9.495
vs HKSE:06938: 16.94
Suzhou Ribo Life Science Co (HKSE:06938) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Suzhou Ribo Life Science Co PS Ratio Related Terms
Suzhou Ribo Life Science Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06938 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Suzhou Ribo Life Science Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Ribo Life Science Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Ribo Life Science Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Suzhou Ribo Life Science Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Suzhou Ribo Life Science Co's Share Price of today is HK$54.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Suzhou Ribo Life Science Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$3.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Suzhou Ribo Life Science Co (HKSE:06938) has a PS Ratio of 16.94 as of Sep. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Suzhou Ribo Life Science Co and its competitors. This is 71% below median its historical median of 58.35. Over the past decade, Suzhou Ribo Life Science Co's PS Ratio has ranged from 16.94 to 80.89. According to the industry distribution chart, Suzhou Ribo Life Science Co ranks #597 out of 936 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Suzhou Ribo Life Science Co's PS Ratio too high?
Suzhou Ribo Life Science Co's current PS Ratio of 16.94 is 71% below median its 10-year median of 58.35. Over the past 10 years, this metric has ranged from a low of 16.94 to a high of 80.89. The Biotechnology industry median PS Ratio is 9.50. Suzhou Ribo Life Science Co's value of 16.94 is 78.4% above this industry median. Based on the distribution chart, Suzhou Ribo Life Science Co ranks #597 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Suzhou Ribo Life Science Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Suzhou Ribo Life Science Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Ribo Life Science Co ranks #597 out of 936 companies for PS Ratio. This places Suzhou Ribo Life Science Co in the lower half of its industry. The industry median PS Ratio is 9.50. Suzhou Ribo Life Science Co's value of 16.94 is 78.4% above this benchmark. Historically, Suzhou Ribo Life Science Co's own PS Ratio has ranged from 16.94 to 80.89 over the past decade. While the company's 10-year median is 58.35 vs. the industry median of 9.50, Suzhou Ribo Life Science Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Ribo Life Science Co's current PS Ratio of 16.94 is 78.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Suzhou Ribo Life Science Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Ribo Life Science Co's current PS Ratio is 16.94, which is 71% below median its own 10-year median of 58.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Ribo Life Science Co stock overvalued right now?
Suzhou Ribo Life Science Co (HKSE:06938) has a current PS Ratio of 16.94. The current PS Ratio is 16.94, which is 71% below median its 10-year median of 58.35 and 78.4% above the Biotechnology industry median of 9.50. Suzhou Ribo Life Science Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Suzhou Ribo Life Science Co (HKSE:06938), the current PS Ratio is 16.94 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA therapeutics. The company's pipeline focuses on cardiovascular, metabolic, renal and liver diseases. Its pipeline includes RBD4059, RBD5044, RBD7007, RBD1119, RBD3103, SR122, SR126, RBD1016, SR112/SR113, among others. It has one reportable operating segment.
9GF Score
Get the complete analysis for HKSE:06938
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06938 has been successfully added to your 
